Astellas Gene Therapies, Inc.

Astellas Gene Therapies, Inc. has announced the closure of its Universal Cells office located in Seattle, resulting in the layoff of 50 employees. This decision reflects the company's strategic shift and realignment of its operations. The closure signifies a significant change for the Seattle office, which has been part of Astellas's efforts to streamline its workforce and focus on core business areas. The layoffs are part of a broader trend in the industry, but specific reasons for this closure were not detailed in the announcement.

Astellas Gene Therapies, Inc. has announced the closure of its Seattle office, resulting in the layoff of approximately 36 employees. This decision comes as part of a strategic shift within the company, which is focusing on its core operations. The layoffs are expected to take effect shortly, impacting the local workforce significantly. The company has not specified the exact reasons for the office closure but indicated a need to streamline operations. This move reflects broader trends in the pharmaceutical industry as companies reassess their operational footprints.

Astellas Gene Therapies, Inc. has announced plans to close its stem cell unit located in Seattle, which will result in layoffs. While the exact number of employees affected has not been disclosed, the closure indicates significant workforce reductions are forthcoming. The decision reflects ongoing strategic adjustments within the company. Further details regarding the timeline for these layoffs have not been provided, leaving uncertainty about the immediate future for employees at this site.